1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Peanut Allergy: Opportunity Analysis and Forecasts to 2027

  • June 2018
  • 124 pages
  • ID: 5575021
  • Format: PDF
  • By GlobalData


Table of Contents

Search Inside

Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Global Peanut Allergy marketplace (8 major pharmaceutical markets - US, France, Germany, Italy, Spain, UK, Canada, and Australia) is to experience intense growth during the forecast period.It is forecasted that the Peanut Allergy market would grow over 1,700-fold between 2017 and 2027.

This incredible growth stems from the projected entry of four new peanut immunotherapy products into a previously empty marketplace. These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics’ AR-101, Prota Therapeutics’ PPOIT, and Camallergy’s CA-002-and one epicutaneous immunotherapy product-DBV Technologies’ Viaskin Peanut.

Peanut allergy has prevalence of 1-2.5% in developed nations and a low rate of remission-only around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors. Currently the only available strategy for managing peanut allergy long-term is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.

Aimmune’s AR-101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies’ Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics’ and Camallergy’s products, PPOIT and CA-002, together are only expected to total 1%. This estimate is based on GlobalData’s assumption that within the forecast period these therapies will each only be released in one geography-Australia and the 5EU respectively.

Growing at a compound annual growth rate (CAGR) of 111% over the 10-year forecast period, in 2027 Peanut Allergy drug sales are projected to reach over $4.5 billion. The majority of sales (88%) will come from the US. This is mainly due to the US having a large population of potential patients (estimated 3,000,000 probable diagnosed prevalent cases), an elevated expected price tag for new therapies (nearly 5-7 times that of the other geographies), and a higher expected treatment rate (based on good accessibility to allergy specialists).

The report, "Peanut Allergy: Opportunity Analysis and Forecasts to 2027", analyzes the peanut allergy treatment landscape and provides detailed insights into the market dynamics of this rapidly developing space. Analysis includes the evaluation of the clinical and commercial profiles of four late-stage pipeline candidates as well as their sales forecasts between 2017 and 2027.

The report specifically -
- Assess the current competitive landscape for peanut allergy and its evolution over the forecast period (2017-2027)
- Evaluate the significance of late-stage pipeline products entering the peanut allergy market and determine how these products will impact the future treatment landscape
- Highlight the critical unmet needs within the peanut allergy market
- Identify opportunities for growth and innovation in the peanut allergy market

- Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global peanut allergy therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Rectal Cancer - Pipeline Review, H2 2019

Rectal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Rectal Cancer - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H2 2019, provides an overview of the Rectal Cancer (Oncology) ...

Grass Pollen Allergy - Pipeline Review, H2 2019

Grass Pollen Allergy - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Grass Pollen Allergy - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H2 2019, provides an overview of the Grass ...

Atherosclerosis - Pipeline Review, H2 2019

Atherosclerosis - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Atherosclerosis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2019, provides an overview of the Atherosclerosis ...


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on